Discounted Cash Flow (DCF) Analysis Unlevered
Larimar Therapeutics, Inc. (LRMR)
$4.49
+0.04 (+0.79%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2018 Projected | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | - | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBITDA (%) | ||||||||||
| EBIT | - | - | - | - | - | - | - | - | - | - |
| EBIT (%) | ||||||||||
| Depreciation | - | - | - | - | - | - | - | - | - | - |
| Depreciation (%) |
Balance Sheet Data
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Total Cash | - | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Cash (%) | ||||||||||
| Account Receivables | - | - | - | - | - | - | - | - | - | - |
| Account Receivables (%) | ||||||||||
| Inventories | - | - | - | - | - | - | - | - | - | - |
| Inventories (%) | ||||||||||
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable (%) | ||||||||||
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) |
Weighted Average Cost Of Capital
| Share price | $ 4.49 |
|---|---|
| Beta | 0.215 |
| Diluted Shares Outstanding | 25.76 |
| Cost of Debt | |
| Tax Rate | 3.31 |
| After-tax Cost of Debt | -5.69% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 5.641 |
| Total Debt | 5.41 |
| Total Equity | 115.67 |
| Total Capital | 121.08 |
| Debt Weighting | 4.47 |
| Equity Weighting | 95.53 |
| Wacc |
Build Up Free Cash
Year A/P | 2018 Projected | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | - | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - | - | - | - |
| Tax Rate | 0.00% | 0.00% | 0.36% | 0.64% | 3.31% | 0.86% | 0.86% | 0.86% | 0.86% | 0.86% |
| EBIAT | - | - | - | - | - | - | - | - | - | - |
| Depreciation | - | - | - | - | - | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventories | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure | -0.11 | -0.08 | -0.06 | -0.33 | -0.10 | - | - | - | - | - |
| UFCF | - | - | - | - | - | - | - | - | - | - |
| WACC | ||||||||||
| PV UFCF | - | - | - | - | - | - | - | - | - | - |
| SUM PV UFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 5.14 |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -21.42 |
| Equity Value | - |
| Shares Outstanding | 25.76 |
| Equity Value Per Share | - |